March 2, 2021 07:03 AM ESTUpdated March 3, 10:10 AM

Introducing Endpoints FDA+, our new premium weekly regulatory news report led by Zachary Brennan

Arsalan Arif

Founder

CRLs. 483s. CBER, CDER and RWE. For biopharma professionals, these acronyms command attention because of the fundamental role FDA plays in drug development. Now Endpoints …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Introducing Endpoints FDA+, our new premium weekly regulatory news report led by Zachary Brennan

Arsalan Arif

Founder

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

New fund will pressure flailing biotechs, as investor frustration boils over

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

J&J reports durability data for bladder cancer 'pretzel' drug after FDA filing

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

In­tro­duc­ing End­points FDA+, our new pre­mi­um week­ly reg­u­la­to­ry news re­port led by Zachary Bren­nan

Founder

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Introducing Endpoints FDA+, our new premium weekly regulatory news report led by Zachary Brennan